A Billion-Dollar Bet on a Protein Most People Have Never Heard Of

When that system breaks, the immune response can spiral out of control, attacking healthy tissue or letting dangerous cells slip through. Electra's approach is to use antibodies that target different SIRP subtypes to selectively take out the troublemakers while leaving the rest of the immune system alone. It's less like carpet-bombing and more like a sniper rifle.

The company's lead drug, ipsoprubart, is a pan-SIRP antibody (meaning it hits multiple SIRP subtypes at once). It's designed to deplete overactive myeloid cells and T cells, the immune soldiers that can go rogue in certain diseases. Right now it's in a global Phase 2/3 registrational trial for secondary hemophagocytic lymphohistiocytosis (sHLH), a rare and often deadly condition where the immune system essentially eats itself. There's also a Phase 1 study in T-cell and NK-cell cancers.

Behind ipsoprubart sits ELA822, a more targeted antibody that goes after only SIRPγ to selectively deplete activated T cells. That one just entered a Phase 1 trial in August 2026, with broader immune and inflammatory diseases in its crosshairs. Plus there are earlier preclinical programs in immunology and immuno-oncology.

The People Behind the Proteins

Electra spun out of Star Therapeutics back in 2018, founded by Star's CEO Adam Rosenthal. The company quietly built its war chest through private rounds: an $84 million Series B in early 2022 (co-led by Westlake Village BioPartners and OrbiMed) and a $183 million Series C in October 2025 that brought in heavyweights like Sanofi, Mubadala Capital, EQT Life Sciences, and Redmile Group.

Running the show today is Kathy Dong, who took over as President and CEO in October 2023. Before Electra, she spent nine years at Gilead Sciences, where she helped launch blockbusters like Sovaldi and Harvoni. That pedigree matters when you're trying to convince public market investors that you know how to actually get a drug across the finish line, not just into a trial.

Why This IPO Tells a Bigger Story

Electra's filing isn't just about one company. It's a litmus test for where the biotech capital markets stand heading into fall 2026.

The bull case is straightforward: a Phase 2/3 asset in a serious rare disease, a fresh Phase 1 program expanding the platform, blue-chip private investors already on the cap table, and a management team with commercial experience. That checks a lot of boxes for the kind of "quality over quantity" deals investors say they want right now.

The bear case? It's still a pre-revenue biotech asking for a near-billion-dollar valuation. Ipsoprubart hasn't reported pivotal data yet. And the IPO market, while improved, can still be fickle; macro uncertainty has a habit of turning risk-on appetite into risk-off caution overnight.

Jefferies' own 2026 outlook describes the current environment as offering "selective pockets of opportunity" rather than a full reopening. Translation: the market will fund good stories, but it won't bail out mediocre ones.

The Bottom Line

Electra Therapeutics is placing a bet that public investors are ready to pay up for a differentiated immunology platform with a registrational-stage asset. If the deal prices well (especially at or above the range), it sends a strong signal that the biotech IPO recovery has real legs heading into Q4.

If it stumbles, it's a reminder that even in a better market, nearly $1 billion is a lot to ask for a promise.

Either way, we'll know soon. The pricing window is open, the roadshow is underway, and Electra is about to find out whether Wall Street thinks its SIRP story is worth the admission price.

Two Shots a Year. Two Infections Out of 2,180 People.

Gilead's twice-yearly lenacapavir injection produced just 2 HIV infections out of 2,180 people in the PURPOSE 2 trial, crushing daily Truvada by 89%. The science is settled; now comes the hard part.